Literature DB >> 1662631

Concentrations of azithromycin in human tonsillar tissue.

G Foulds1, K H Chan, J T Johnson, R M Shepard, R B Johnson.   

Abstract

Patients scheduled to undergo tonsillectomy were administered 500 mg oral azithromycin as two 250 mg capsules given 12 h apart. Between 9 h and one week after the second dose, tonsil samples were taken during surgery and assayed for azithromycin. Mean concentrations in tonsillar tissue, 12 and 24 h after the second of the two 250 mg doses given 12 h apart, were 4.5 and 3.9 micrograms/g, respectively. Concurrent mean serum concentrations were approximately 0.03 and 0.01 micrograms/g, respectively. The mean concentration in tonsillar tissue 7.5 days after the last dose was 0.93 micrograms/g. The apparent half-life of drug in the tissue was 76 h. The ratio of mean concentration in tissue to that in serum was greater than 150-fold for all time intervals. The presence of high azithromycin concentrations in tonsillar tissue suggests that a once-daily regimen over five days or less may be effective in treating tonsillo-pharyngitis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662631     DOI: 10.1007/bf01975840

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  16 in total

1.  Concentration of azithromycin in human prostatic tissue.

Authors:  G Foulds; P Madsen; C Cox; R Shepard; R Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

2.  In-vitro activity of erythromycin, roxithromycin and CP 62993 against common paediatric pathogens.

Authors:  S C Aronoff; C Laurent; M R Jacobs
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

3.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

4.  Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae.

Authors:  F W Goldstein; M F Emirian; A Coutrot; J F Acar
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

5.  Comparison of the acid stability of azithromycin and erythromycin A.

Authors:  E F Fiese; S H Steffen
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo.

Authors:  J A Retsema; A E Girard; D Girard; W B Milisen
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

7.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

8.  Rate of bactericidal activity for Branhamella catarrhalis of a new macrolide, CP-62,993, compared with that of amoxicillin-clavulanic acid.

Authors:  E Yourassowsky; M P van der Linden; M J Lismont; F Crokaert; Y Glupczynski
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

9.  Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1).

Authors:  J A Washington; W R Wilson
Journal:  Mayo Clin Proc       Date:  1985-03       Impact factor: 7.616

10.  Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides.

Authors:  G M Bright; A A Nagel; J Bordner; K A Desai; J N Dibrino; J Nowakowska; L Vincent; R M Watrous; F C Sciavolino; A R English
Journal:  J Antibiot (Tokyo)       Date:  1988-08       Impact factor: 2.649

View more
  14 in total

1.  Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye.

Authors:  S Jaruratanasirikul; R Hortiwakul; T Tantisarasart; N Phuenpathom; S Tussanasunthornwong
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

2.  Concentration of azithromycin in human prostatic tissue.

Authors:  G Foulds; P Madsen; C Cox; R Shepard; R Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 3.  The pharmacokinetics of azithromycin and their clinical significance.

Authors:  H Lode
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

4.  Effects of environmental factors on the in vitro potency of azithromycin.

Authors:  J A Retsema; L A Brennan; A E Girard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

5.  Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group.

Authors:  B O'Doherty
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-09       Impact factor: 3.267

6.  Single-Arm Open-Label Clinical Trial of Two Grams of Aztreonam for the Treatment of Neisseria gonorrhoeae.

Authors:  Lindley A Barbee; Olusegun O Soge; Negusse Ocbamichael; Angela LeClair; Matthew R Golden
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 7.  Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction.

Authors:  Arlene C Seña; Laura Bachmann; Christine Johnston; Teodora Wi; Kimberly Workowski; Edward W Hook; Jane S Hocking; George Drusano; Magnus Unemo
Journal:  Lancet Infect Dis       Date:  2020-06-19       Impact factor: 25.071

Review 8.  Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.

Authors:  C J Dunn; L B Barradell
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

9.  Macrolides: A Canadian Infectious Disease Society position paper.

Authors:  S McKenna; G Evans
Journal:  Can J Infect Dis       Date:  2001-07

Review 10.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.